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Abstract: The majority of patients diagnosed with rheumatoid arthritis (RA) have developed
autoantibodies against neoepitopes in proteins that have undergone post-translational modification,
e.g., citrullination or carbamylation. There is growing evidence of their molecular relevance and
their potential utility to improve diagnosis, patient stratification, and prognosis for precision
medicine. Autoantibodies reacting to native proteins may also have a role in RA pathogenesis,
however, their reactivity patterns remain much less studied. We hypothesized that a high-density
protein array technology could shed light onto the normal and disease-related autoantibodies
produced in healthy and RA patient subgroups. In an exploratory study, we investigated the global
reactivity of autoantibodies in plasma pools from 15 anti-cyclic citrullinated peptide (CCP)-positive
and 10 anti-CCP-negative RA patients and 10 healthy donors against more than 1600 native and
unmodified human proteins using a high-density protein array. A total of 102 proteins recognized
by IgG autoantibodies were identified, hereof 86 were recognized by antibodies from CCP-positive
RA patients and 76 from anti-CCP-negative RA patients, but not by antibodies from healthy donors.
Twenty-four of the identified autoantigens have previously been identified in synovial fluid. Multiple
human proteins in their native conformation are recognized by autoantibodies from anti-CCP-positive
as well as anti-CCP-negative RA patients.
Keywords: protein array; rheumatoid arthritis; autoantibodies; native autoantigens;
immunome; microarray
1. Introduction
Rheumatoid arthritis (RA) is the most common systemic autoimmune disease characterized
by synovial inflammation that can cause joint damage, disability, and may be associated with
increased prevalence of systemic manifestations, including, e.g., cardiovascular comorbidities [1].
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The identification of novel autoantibodies and autoantibody reactivity patterns may improve our
understanding of pathogenesis and enable personalized stratification of patients into subsets that may
benefit from different treatment modalities [2–6].
Before disease phenotype onset, a pre-RA phase lasting months to years, may be characterized
by the presence of circulating autoantibodies in biofluids, increasing concentration and range of
inflammatory cytokines and chemokines, and altered metabolism [7]. Around 2/3 of RA patients
produce anti-citrullinated protein antibodies (ACPAs), measured in vitro as anti-CCP antibodies,
which are utilized as key clinical diagnostic biomarkers in RA [8,9]. The etiopathogenesis and clinical
course of this patient subset differ from those of ACPA-negative RA patients [10]. However, both
ACPA-positive and ACPA-negative patients show antibody reactivity against native proteins [11–14].
During the last five years, more than 20 native proteins have been found to be recognized by
autoantibodies from RA patients [15,16]. In a recent study, antibody reactivity against native hnRNP
A2/B1 (RA33) was found in synovial fluid from RA patients, primarily those with early RA, whereas
antibodies against citrullinated RA33 were primarily found in patients with a longer disease duration
and more erosive disease [17]. This challenges the common view that the loss of tolerance depends on
citrullination [18,19]. Furthermore, a recent study by Zheng et al. demonstrated the binding of IgG
antibodies to native peptides in anti-CCP- and rheumatoid factor (RF)-positive RA, even to peptides
that do not contain arginine or lysine and therefore are not likely to be recognized by cross-reacting
antibodies against citrulline or homocitrulline [20]. This underlines the importance of investigating
antibody reactivity against native proteins being autoantigen targets in RA. Such efforts are supported
by novel technologies such as multiplex platforms and high-density protein arrays providing a high
sensitivity, high reproducibility and high dynamic range [21–23].
Here, we investigate the autoantibody reactivity against native (non-post translational modified)
full-length proteins in anti-CCP-positive and anti-CCP-negative RA patients using a microarray
containing more than 1600+ immune-related native human proteins to explore the complement of
autoantibodies against native proteins in humans.
2. Experimental Section
2.1. Collection of Plasma Samples
Plasma was isolated from 15 anti-CCP-positive RA patients with median anti-CCP levels of
274 mU (age: 52.8 ± 15.6 (27–84), sex: 10 female, 2 male, and 3 unknown, DAS28-ESR: 5.1 ± 1.4,
DAS28-CRP: 4.7 ± 1.2, CRP (mg/L): 29.4 ± 31.8, anti-CCP: 531.2 ± 526.8, RF IgM: 91.7 ± 126.3, 5 in
csDMARDs treatment and 13 in bDMARDs treatment), 10 anti-CCP-negative patients with median
anti-CCP levels of 7.9 mU (age: 53.8 ± 17.1 (34–81), sex: 5 female and 5 male, DAS28-ESR: 3.7 ± 0.8,
DAS28-CRP: 4 ± 1.2, CRP (mg/L): 12.6 ± 8.9, anti-CCP: 6.1 ± 6.4, RF IgM: 21.6 ± 19.7, 1 in csDMARDs
treatment and 7 in bDMARDs treatment), and 10 anti-CCP-negative healthy donors. Plasma from each
group were pooled prior to analysis. The RA patients fulfilled the American College of Rheumatology
and European League Against Rheumatism criteria for RA diagnosis [1], and the ethics committee of
the Institute of Rheumatology in Prague, Czech Republic, approved the use of patient samples after
informed patient consent (26 June 2012, No. 3294/2012). Plasma samples from donors attending the
Blood Bank at Copenhagen University Hospital, Rigshospitalet, were used as controls. All healthy
blood donors were anonymous to the investigators.
2.2. Protein Microarray Treatment
After the removal of storage buffer, Immunome™ protein microarrays containing
1600+ immune-related human proteins in a native configuration spotted in quadruplicates
(Sengenics, Singapore) were washed twice in cold phosphate-buffered saline (PBS) at 4 ◦C using
a Pap jar (Fischer scientific, Pittsburgh, PA, USA) and were wiped at the edges between each wash.
Subsequently, the microarrays were added to the quadriperm chamber (Greiner BioOne, Kremsmünster,
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Austria) containing the reaction buffer (1 mM Dithiothreitol, 10 mM CaCl2, 100 mM Tris-HCl) and
incubated at 37 ◦C for 3 h while shaking at 50 rpm. Slides were removed, dried, and washed in cold
serum albumin buffer (SAB) (0.1% Triton X-100, 0.1% bovine serum albumin in PBS) in a slide tube,
inverted 4 times and shaken for 5 min at 50 RPM on a shaker (IKA, Germany, Königswinter). This step
was repeated once with new SAB buffer. Then, 30 µL pooled plasma from patients or healthy controls
(diluted 1:200 in SAB buffer) was added, and the slides were incubated on a shaker for 2 h at ambient
temperature (20 ◦C) at 50 RPM. The slides were removed from the chamber, dried, and washed in a
slide tube containing SAB buffer by inverting them 4 times and shaking them for 20 min on a shaker at
50 RPM at ambient temperature. This was repeated twice and followed by incubation in a quadriperm
chamber containing SAB buffer and Cy3 conjugated (GE Healthcare, Chicago, Ill, USA) polyclonal
rabbit anti-human IgG (Dako, Santa Clara, CA, USA), diluted 1:1000 (v/v) and covered in tinfoil for 2 h
at 50 RPM on a shaker at ambient temperature. The slides were then removed and washed with 30 mL
SAB buffer on a shaker for 5 min at 50 RPM at ambient temperature, which was repeated once and
followed by washing in ultrapure water. Finally, the slides were centrifuged at 240 G for 5 min in a
new slide tube in order to dry. Slides were scanned on a high-resolution slide reader (Innoscan 710AL,
Innopsys, Carbonne, France) using the Mapix software (Ver. 8.2.2, Innopsys). The chosen scan settings
were a 532 nm laser with a low laser power (5V), PMT gain at 60%, 5 µm resolution, and a scan speed
of 35 px/sec. The images were exported as TIF format to ensure high-quality pictures.
2.3. Extraction of Quantitative Expression Data
Scanned images of the microarrays were imported to Spotxel (SICASYS, v1.7.6, Heidelberg,
Germany). The GAL file specific for the Immunome™microarray automatically aligned the protein
spot grid using Spotxel. This was followed by quantification of the array using the Flex-Spot option
ensuring that every protein spot was included, even if the spot differed from the specific location
specified by the GAL file coordinates. Following quantification, we examined the boundaries of
the protein spots to ensure that they represented the protein spots, and that any artifact present on
the microarray was not included in the analysis. The raw data were imported to R (Ver 1.1.456,
R Core Team), and data were processed using an in-house developed R analysis. Raw data can be
found in Table S1.
2.4. Data Analysis Pipeline
Scanned Raw intensity values were used to normalize the data using a combination of quantile- and
intensity-based normalization as described [24]. Normalized expression values were used to calculate
a Z-score, coefficient of variation (CV), and Chebyshev inequality precision (CI-P) for each protein.
Cut-off values were Z-score > 2, Intra-protein CV < 15, and CI-P < 0.05. These restrictions were
applied in order to filter low intensities away, ensuring high reproducibility between quadruplicates,
and to make sure the intensities did not belong to the negative control distribution. Quality control
for the secondary antibody used included positive and negative immunoglobulin controls which
confirmed the high-quality labeling efficiency and spot detection of the secondary antibody. Spots
included IgG for a positive control and IgA and IgM for negative controls (Figure 1). Following data
filtering, we applied a two-sample t-test with a Benjamini–Hochberg false discovery rate to identify
statistically significant results. Fold changes for the filtered results were calculated between each
patient/donor group.
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Figure 1. Immunome microarray images and corresponding quality control plots. Pooled plasma
from anti-cyclic citrullinated peptide (CCP)-negative healthy donors (n = 10), anti-CCP-negative
rheumatoid arthritis (RA) patients (n = 10), or anti-CCP-positive RA patients (n = 15) were added
to Immunome™ microarrays containing human proteins in their native configuration spotted in
quadruplicates on each microarray. The binding of IgG autoantibodies was subsequently detected using
fluorescence-labelled goat anti-human IgG antibodies and scanned on an Innoscan 710AL slide reader.
(A) Scanned microarrays containing one of the four replicates on each microarray. Fluorescent spots
indicate positive binding of autoantibodies from plasma. (B) Intra-protein coefficient of variation (CV)
for six IgG-positive control spots on the microarray demonstrating bound anti-human IgG antibody.
(C) Negative control spots for secondary IgG antibody alone showing no binding to IgA or IgM
replicates or the marker of correct protein-folding, biotin-carboxyl carrier protein (BCCP), or bovine
serum albumin (BSA).
3. Results
Pools of plasma from 15 anti-CCP-positive RA patients, 10 anti-CCP-negative RA patients, and
10 anti-CCP-negative healthy donors were each applied to the commercially available Immunome™
Discovery microarray consisting of more than 1600+ different human proteins from different protein
families including kinases, signaling molecules, cytokines, interleukins, chemokines, and cancer
antigens [25,26] (Figure 1 and Figure S1).
The average intensities measured across all three conditions were all relatively low (< 2500 relative
fluorescence units (RFU)), indicating low antibody activity against most proteins. The top 10% highest
intensities associated with the anti-CCP-positive plasma reached an average intensity of 12,500 RFU,
while less than half and around 1/10 of this intensity were observed after incubation with plasma from
the anti-CCP-negative patients and healthy donors, respectively (Figure S2).
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3.1. Identification of Native Autoantigens
We identified 102 native proteins that were recognized by antibodies in the anti-CCP-positive
plasma pool and/or the anti-CCP-negative plasma pool, with fold changes ranging from two to more
than 100 compared with the plasma pool from healthy donors (Figure 2 and Table S2 and Table S3). Of
these, 23 have previously been identified as autoantigens according to the human autoantigen database
AagAtlas [27]. Gene ontology (GO) annotation analysis of the identified proteins’ molecular functions
categorized several of them as involved in either the binding or catalytic activity (Figure 2B,C). The
remaining proteins could either not be assigned a GO annotation (Figure 2A) or were involved in
molecular function regulation or transducer activity, or structural molecular activity or transcription
regulator activity (Figure 2D).
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Figure 2. Native proteins recognized by antibodies from anti-CCP-positive and anti-CCP-negative
RA patients. Pooled plasma from healthy donors (HD, n = 10), anti-CCP-positive RA patients
(positive, n = 15), and anti-CCP-negative RA patients (negative, n = 10) were tested for antibody
reactivity against 1600+ immune-related native human proteins using the Immunome™ protein
microarray. Shown are four different heatmaps categorized according to the antigens’ gene ontology
annotation. The values represented are the antibody reactivities expressed as relative fluorescence
units (RFU). (A) Proteins that could not be assigned a molecular function GO annotation, (B) proteins
involved in binding, (C) proteins involved in catalytic activity, and (D) the GO annotation other includes
molecular function regulator and transducer activity, structural molecule activity, and transcription
regulator activity. Proteins included in the figure meet the following criteria: Fold change > 2, z-score > 2,
intra-protein percentage coefficient of variation (%CV) < 15, Chebyshev inequality precision (CI-P) <
0.05, and p-value < 0.05.
Of the 102 autoantigens identified in this study, 86 and 76 were recognized by antibodies from
anti-CCP-positive and anti-CCP-negative RA patients, respectively, with an overlap of 61 proteins.
Among the overlapping proteins, 12 were listed as known autoantigens in the AagAtlas dataset:
alpha-crystallin B chain, fibroblast growth factor receptor 1 (FGFR1), histone deacetylase 1 and 3,
Biomedicines 2020, 8, 141 6 of 13
keratin type I cytoskeletal 15 and 19 (KRT15 and KRT19), mitogen-activated protein kinase 9, melanoma
antigen recognized by T-cells 1, photoreceptor-specific nuclear receptor, serologically defined colon
cancer antigen 8, endophilin-A2, and vimentin.
One protein, FAS-associated factor 1, was recognized by antibodies from healthy donor plasma
to a moderately higher degree than by antibodies from anti-CCP-positive RA plasma (2300 RFU vs.
1000 RFU). The antibody binding was generally higher in the presence of anti-CCP-positive plasma
than in presence of anti-CCP-negative plasma or healthy donor plasma (Figures 1 and 2).
The biggest fold differences in antibody binding between anti-CCP-positive RA patients and
healthy donors were observed for spots containing the calcium-regulated heat-stable protein 1
(35-fold compared with healthy donor plasma), testis-specific Y-encoded protein 3 (28-fold), and
Cytosolic Fe-S cluster assembly factor NUBP2 (28-fold) (Figure 2 and Table S2). The biggest differences
between anti-CCP-negative and healthy donors were found for SSB (121-fold), cancer/testis antigen
47A (23-fold), and glutathione S-transferase theta-1 (18-fold). Of these, only SSB has previously been
identified as an autoantigen according to the human autoantigen database AagAtlas.
3.2. Differences in Antibody Reactivity between Anti-CCP-Positive and Anti-CCP-Negative Plasma
For 71 proteins, significantly stronger reactions were observed in the presence of anti-CCP-positive
than in the presence of anti-CCP-negative RA patient plasma (Figure 2, Table S2 and Table S3). The
opposite was true for four proteins (SSB, zinc finger protein 496, BAG family molecular chaperone
regulator 3, and phosducin-like 3). The differences were generally less than 5-fold. SSB showed 19 times
higher antibody binding after incubation with anti-CCP-negative plasma than with anti-CCP-positive
plasma, while the binding to zinc finger protein 496, BAG family molecular chaperone regulator 3,
and phosducin-like 3 was up to 4-fold higher.
A total of 15 out of the 75 mentioned proteins showing differential antibody binding (71 highest in
the presence of anti-CCP-positive plasma, and 4 highest in the presence of anti-CCP-negative plasma)
have previously been identified as a disease-related autoantigen according to the AagAtlas database.
3.3. Antigens Identified in Synovial Fluid
In the search for potentially pathogenic RA autoantigens, we investigated which of the
102 identified autoantigens are present in synovial fluid proteome, essentially being a plasma
filtrate [28]. We found 24 proteins that have previously been shown to be present in synovial fluid
(Table 1). Extracellular proteins included vimentin, acetyl-CoA acetyltransferase, fructose-bisphosphate
aldolase A, KRT19, L-lactate dehydrogenase, macrophage migration inhibitory factor, transketolase,
tropomyosin, carcinoembryonic antigen-related cell adhesion molecule 1, elongation factor 1-gamma,
and inosine-5′-monophosphate dehydrogenase 1. Especially KRT19 showed high binding intensity after
incubation with plasma from anti-CCP-positive RA patients compared with plasma from healthy donors
(17-fold). Of note, IgG antibodies against immunoglobulin heavy constant gamma 1 (IgG rheumatoid
factor) were also identified with a 4- and 3-fold increase after incubation with anti-CCP-positive plasma
and anti-CCP-negative plasma compared with healthy donor plasma.
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Table 1. Synovial fluid proteins identified as autoantigens in this study.*.
Gene Name Protein Name Localization †
IGHG1 (IgG1) Immunoglobulin heavy constant gamma 1 Extracellular/cell associated
ACAT2 Acetyl-CoA acetyltransferase Intracellular and extracellular
ALDOA Fructose-bisphosphate aldolase A Intracellular and extracellular
CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 Intracellular and extracellular
EEF1G Elongation factor 1-gamma Intracellular and extracellular
IMPDH1 Inosine-5’-monophosphate dehydrogenase 1 Intracellular and extracellular
KRT19 Keratin 19 Intracellular and extracellular
LDHB L-lactate dehydrogenase B chain Intracellular and extracellular
MIF Macrophage migration inhibitory factor Intracellular and extracellular
TKT Transketolase Intracellular and extracellular
TPM3 Tropomyosin alpha-3 chain Intracellular and extracellular
VIM Vimentin Intracellular and extracellular
CAMK2G Calcium/calmodulin-dependent protein kinase type II subunit gamma Intracellular
CARHSP1 Calcium-regulated heat-stable protein 1 Intracellular
EEF1D Elongation factor 1-delta Intracellular
IFI35 Interferon-induced 35 kDa protein Intracellular
ILF2 Interleukin enhancer-binding factor 2 Intracellular
PRKAR1A cAMP-dependent protein kinase type I-alpha regulatory subunit Intracellular
PSME3 Proteasome activator complex subunit 3 Intracellular
RPLP1 60S acidic ribosomal protein P1 Intracellular
RUFY1 RUN and FYVE domain-containing protein 1 Intracellular
SSB Lupus La protein / SSB Intracellular
STAT1 Signal transducer and activator of transcription 1-alpha/beta Intracellular
TPM1 Tropomyosin alpha-1 chain Intracellular
* Identified in synovial fluid in the following studies [29–31]. † According to uniprot.org.
4. Discussion
While antibody binding to post-translationally modified antigens in RA has been studied
intensively, few studies have investigated the binding of the patients’ antibodies to native
autoantigens [11–16,18]. To our knowledge, this study is the first to use high-density protein arrays for
native autoantigen profiling in RA.
The existence of polyreactive, naturally occurring autoantibodies, mainly of IgM but also of other
Ig isotypes, has been known for decades [32]. However, in this study, we focused on IgG autoantibodies.
We identified 102 native proteins as potential autoantigens. Antibodies from anti-CCP-positive patients
recognized 86 of these proteins, at least 18 of which have previously been identified as autoantigens [27].
Of these, both native and citrullinated vimentin is a known target for autoantibodies in RA, while
interleukin-1 alpha and KRT8 are recognized in their native state [33–36]. Autoantibodies against
native KRT15 were found in patients suffering from RA with secondary vasculitis [37]. The remaining
14 autoantigens have been identified in diseases such as multiple sclerosis, asthma, and cancer [38–40].
Antibodies in anti-CCP-negative plasma recognized 76 proteins, 17 of which have previously been
shown to be recognized by autoantibodies. Of these, three proteins have been targets for autoantibodies
in RA including the aforementioned KRT15 and vimentin, but also SSB, which is recognized in its
native state [41,42].
This study identifies 12 proteins recognized by antibodies contained in both anti-CCP-positive
and anti-CCP-negative RA plasma that are also listed as autoantigens in the AagAtlas database, but not
necessarily to RA. This includes vimentin, cytokeratins KRT15 and KRT19, and FGFR1.
Vimentin is an intracellular protein that is also known to be secreted from activated macrophages
and expressed on the cellular surface of monocytes [43,44]. Post-translationally modified vimentin,
e.g., phosphorylation, ubiquitination, carbamylation, and citrullination, has been extensively studied
and shown to be involved in several diseases including RA, systemic lupus erythematosus, and
ankylosing spondylitis [45–50]. It is a promising diagnostic and prognostic marker in RA with
sensitivity and specificity comparable to anti-CCP [51–54]. The role of native vimentin is much less
studied in RA, but it may prove a useful biomarker.
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The cytokeratins KRT15 and KRT19 in native form appeared to be targets for autoantibodies in both
anti-CCP-positive and anti-CCP-negative RA, and with a 17-fold increase over the background signal
defined by donor serum, and native KRT19 stood out as a prominent autoantigen in anti-CCP-positive
RA. It has not previously been suggested as an autoantigen in RA, but IgG autoantibodies against
KRT19 have been identified in serum from mice exposed to cigarette smoke [55], which is notable
given the strong association between smoking and anti-CCP-positive RA [56]. Even though it is
possible for intracellular antigens to be bound by antibodies outside the cell, e.g., after leakage from
dying cells, extracellular antigens are presumably more likely to form pathogenic complement- and
leukocyte-activating immune complexes with autoantibodies than intracellular antigens.
An apparent paradoxical reactivity was observed against FGFR1, a member of the FGFR family
which acts as a receptor for specific fibroblast growth factor (FGF) family members that are important
homeostatic growth factors in joint tissue and regulate cartilage homeostasis [57,58]. FGF2 binding to
FGFR1 leads to angiogenesis which is part of the pathogenesis of RA during pannus formation [59,60].
Another result of FGFR1 activation by FGF2 promoted the catabolism and impeded the anabolism of
human articular chondrocytes [61]. Thus, signaling through FGFR1 potentially has a degenerative
function in the joint, and blocking antibodies may therefore be protective. It remains to be shown
whether the anti-FGFR1 antibodies demonstrated in this study are receptor-blocking or stimulatory;
theoretically, a stimulatory effect may be pathogenic.
SSB was identified as an autoantigen in anti-CCP-negative RA, specifically. The production of
anti-SSB antibodies is a hallmark of Sjögren’s syndrome, but can also be found in systemic lupus
erythematosus [62] and RA patients [41,63]. Since we used pooled plasma in this study, one or a few
patients in the anti-CCP-negative cohort may be responsible for this reactivity. The overlap between
RA and lupus, referred to as “rhupus”, is well-described [64]. However, none of the patients included
in the cohort were diagnosed with systemic lupus erythematosus.
The finding of IgG autoantibodies against IgG1, i.e. IgG rheumatoid factor (IgG RF), in pools
of both anti-CCP-positive and anti-CCP-negative plasma was expected. Although there is overlap
between ACPA and RF production, it is well-recognized that RF is also produced by subsets of
ACPA-negative patients [65,66].
Rheumatoid arthritis is characterized by synovial inflammation. The synovial membrane is in
direct contact with the synovial fluid within the joints making the synovial fluid interesting in RA
due to being present at the site of inflammation. Although this study used plasma to investigate the
presence of autoantibodies in RA patients, synovial fluid is an ultrafiltrate from plasma. Thus, the
proteomes share many similarities, however, plasma lack the proteins secreted from the surrounding
tissue in the synovium [28,67–69]. For these autoantigens to be pathologically relevant, we suspect
they need to be at the site of disease in the joints. Therefore, it is interesting whether the identified
autoantigens previously have been identified in synovial fluid as well. Following this logic, we identify
24 potential pathologically relevant autoantigens. The pathological events leading to inflammation in
RA may be due to the generation of immune complexes that drive the local production of antibodies
against native proteins within the joint, just like the suggested action of ACPAs’ presence in the
synovial joint [70]. However, whether the identified autoantigens present in synovial fluid are indeed
pathologically relevant is not known.
A limitation to our study is the use of pooled plasma samples, which do not allow a demonstration
of differences between individual patients or subgroups of RA patients. Patients with RA often present
with different symptoms, signs, and response to treatment [71–74]. Even patients presenting with the
same clinical symptoms may differ with respect to cell infiltration, cytokine involvement, and gene
activation and expression [75–79]. The design of custom arrays specifically for RA including both
known autoantigens, native as well as post-translationally modified autoantigens, and novel promising
targets would enable a thorough stratification of RA patients based on their antibody fingerprint,
benefitting personalized diagnosis and treatment.
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5. Conclusions
This study explored the autoantigen repertoire in normal and RA patients. We identify several
native autoantigens recognized by autoantibodies in both anti-CCP-positive and anti-CCP-negative
RA including vimentin, FGFR1, KRT15, and KRT19. This demonstrates that autoimmunity in RA is
not restricted to post-translationally modified epitopes, and that reactivity against native proteins is
higher in anti-CCP-positive RA plasma than in anti-CCP-negative RA plasma.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2227-9059/8/6/141/s1.
Figure S1: Scanned Immunome microarray, Figure S2: General intensity of rheumatoid arthritis and healthy
donor plasma, Table S1: Excel document containing all information about protein spots on the microarray and
their corresponding relative fluorescence unit intensity from plasma antibody binding from healthy donors and
anti-CCP-positive and anti-CCP-negative RA patients, Table S2: Fold changes for all filtered positive hits between
all 3 conditions, Table S3: Unique targeted antigens in one of the two rheumatoid arthritis conditions.
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